Senolytic Drug Duo Reverses Arterial Aging by Clearing Zombie Cells
Eight months of dasatinib plus quercetin treatment restored blood vessel function in aged mice by eliminating senescent endothelial cells.
Summary
Researchers found that long-term treatment with dasatinib and quercetin (D+Q), a senolytic drug combination, significantly reduced vascular endothelial senescence in aged mice. Administered biweekly for eight months, D+Q lowered key senescence markers, restored the enzyme eNOS to its normal nitric oxide-producing form, reduced mitochondrial dysfunction and oxidative stress, and recovered endothelium-dependent vasodilation. Transcriptomic analysis revealed activation of the relaxin signaling pathway and upregulation of nitric oxide synthase genes. The findings suggest that periodically clearing senescent cells from blood vessel walls can meaningfully reverse age-related arterial dysfunction, pointing toward a viable therapeutic strategy for cardiovascular aging.
Detailed Summary
Cardiovascular disease remains the leading cause of death in aging populations, and a key early driver is the progressive dysfunction of the endothelium — the thin cellular lining of blood vessels. As endothelial cells accumulate damage over time, they enter a state called senescence, ceasing normal function while secreting inflammatory signals that degrade surrounding tissue. This study asked whether periodically eliminating these senescent cells could preserve vascular health over the long term.
Researchers administered dasatinib (5 mg/kg) plus quercetin (50 mg/kg) — a widely studied senolytic combination — to aged mice every two weeks for eight months. They also tested the drugs on senescent human umbilical vein endothelial cells (HUVECs) in vitro. Senescence burden was assessed via p21 protein levels and SA-β-galactosidase staining, while vascular function was evaluated through acetylcholine-stimulated vasodilation assays in mesenteric arteries.
D+Q significantly reduced senescence markers in both aged mouse arteries and HUVECs. Mechanistically, treatment reversed age-related uncoupling of endothelial nitric oxide synthase (eNOS), promoting its active dimeric form and boosting nitric oxide bioavailability — a critical mediator of vascular tone. Mitochondrial health improved markedly, with restored ultrastructure, reduced mitochondrial mass accumulation, and lower reactive oxygen species production. Transcriptomic data pointed to activation of the relaxin signaling pathway and upregulation of multiple NOS isoforms as key molecular mechanisms.
Functionally, treated aged mice showed restored endothelium-dependent vasodilation and improved blood flow, outcomes that typically deteriorate with age. These results reinforce the concept that senescent cell accumulation is a root cause — not merely a byproduct — of arterial aging.
Caveats include the mouse-only in vivo model, the use of a single dosing regimen, and the absence of human clinical data. Long-term safety and optimal dosing for humans remain to be established.
Key Findings
- D+Q biweekly for 8 months significantly reduced p21 and SA-β-gal senescence markers in aged mouse arteries.
- Treatment reversed eNOS uncoupling, restoring nitric oxide production and endothelium-dependent vasodilation.
- Mitochondrial ultrastructure, mass, and ROS levels were normalized in endothelial cells after D+Q treatment.
- Transcriptomics revealed activation of the relaxin signaling pathway and upregulation of NOS isoforms.
- Aged mesenteric arteries showed restored blood flow response to acetylcholine stimulation after senolytic therapy.
Methodology
Aged mice received dasatinib plus quercetin biweekly for 8 months; vascular function was assessed via ex vivo mesenteric artery vasodilation assays. In vitro experiments used senescent HUVECs, and transcriptomic analysis was performed to identify mechanistic pathways. Senescence was quantified by p21 protein expression and SA-β-galactosidase staining.
Study Limitations
All in vivo data derive from mice, and species differences in vascular biology limit direct translation to humans. Only one dosing protocol was tested, leaving open questions about optimal frequency, dose, and treatment window. Long-term safety of repeated dasatinib exposure — a chemotherapy agent — in healthy aging individuals has not been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.